Pampa Energía S.A. logo PAM - Pampa Energía S.A.

Price: -- -- | CONSENSUS: Buy DETAILS
STRONG
BUY
0
BUY 4
HOLD 4
SELL 0
STRONG
SELL
0
| PRICE TARGET: $97.00 DETAILS
HIGH: $97.00
LOW: $97.00
MEDIAN: $97.00
CONSENSUS: $97.00
UPSIDE: 20.23%

Stock News

Addex Reports Full Year 2025 Financial Results and Provides Corporate Update

Addex Reports Full Year 2025 Financial Results and Provides Corporate Update

GABAB PAM chronic cough candidate continued towards clinic after demonstrating robust anti-tussive activity in multiple disease models Continued to reposition dipraglurant mGlu5 NAM for brain injury recovery Entered option and collaboration agreement with Sinntaxis for exclusive license to intellectual property covering the use of mGlu5 NAM in brain injury recovery Regained rights to phase 2 mGlu2 PAM asset, ADX71149 Partner, Indivior advanced GABAB PAM substance use disorders program successfully through IND enabling studies Strategic investment in Stalicla SA, confirming commitment to advancing innovative treatments for neurological disorders Cash position of CHF 1.6 million at December 31, 2025 Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, April 30, 2026 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, today reported its full-year 2025 financial results for the period ended December 31, 2025, and provided a corporate update.

Apr 29, 2026 09:00 PM globenewswire.com
Addex GABAB PAM Candidate Demonstrates Solid Anti-Tussive Activity in Bleomycin IPF-Related Chronic Cough Model

Addex GABAB PAM Candidate Demonstrates Solid Anti-Tussive Activity in Bleomycin IPF-Related Chronic Cough Model

Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, April 29, 2026 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, announced today encouraging preclinical data demonstrating antitussive activity of its GABAB positive allosteric modulator (PAM) candidate in a bleomycin (BLM)-induced idiopathic pulmonary fibrosis (IPF) exacerbated chronic cough model.

Apr 28, 2026 09:00 PM globenewswire.com
Pampa Energía: No New Catalysts, But Potential In Prices

Pampa Energía: No New Catalysts, But Potential In Prices

Pampa Energía is now rated a Buy, offering exposure to Argentina's energy sector amid shifting oil price dynamics. Despite recent oil price surges, PAM shares underperformed peers due to its diversified revenue mix, with significant weight in gas and electricity. Long-term oil price uncertainty persists, but PAM's profitability risk from sub-$60 crude has eased, given current geopolitical disruptions.

Apr 21, 2026 09:27 PM seekingalpha.com
Addex GABAB PAM Candidate Demonstrates Robust Anti-Tussive Activity in Non-Human Primate Chronic Cough Model

Addex GABAB PAM Candidate Demonstrates Robust Anti-Tussive Activity in Non-Human Primate Chronic Cough Model

Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, April 21, 2026 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, announced today robust anti-tussive activity of its novel gamma-aminobutyric acid sub-type B receptor (GABAB) positive allosteric modulator (PAM) in a non-human primate (NHP) chronic cough model.

Apr 20, 2026 09:00 PM globenewswire.com
Pampa Energía Informs the Market that it has Filed its Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2025

Pampa Energía Informs the Market that it has Filed its Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2025

BUENOS AIRES, AR / ACCESS Newswire / April 9, 2026 / Pampa Energía S.A. (NYSE:PAM)(Buenos Aires Stock Exchange:PAMP) ('Pampa' or the 'Company'), one of Argentina's largest energy companies, participating mainly in the crude oil, gas and power generation value chain, announces that on April 9, 2026 it has filed its annual report on Form 20-F for the fiscal year ended December 31, 2025 (the '2025 Annual Report') before the U.S. Securities and Exchange Commission (the 'SEC').

Apr 09, 2026 03:00 AM accessnewswire.com

Price Targets